Nuvelo, Inc. Announces Upcoming Conference Calls, Webcasts And Conference Participation
SAN CARLOS, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold the following events in November:
Third Quarter 2005 Financial Results and Accomplishments Conference Call & Webcast November 1, 2005 4:30 p.m. ET Dr. Ted W. Love, CEO & Chairman Dr. Michael Levy, SVP, Research & Development Gary Titus, VP Finance & Chief Accounting Officer Dial in: 800-510-0146 domestic and 617-614-3449 international Conference ID: 19105503 Replay: 888-286-8010 domestic and 617-801-6888 international Conference ID: 94413845 Webcast: www.nuvelo.com or you can access it through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site. CIBC World Markets 16th Annual Healthcare Conference November 9, 2005 2:00 p.m. ET Lee Bendekgey, SVP and CFO http://conferences.cibcwm.com/health05/ (password: november) Update on Nuvelo's cardiovascular programs, including a discussion of the rNAPc2 Phase 2a acute coronary syndromes (ACS) data that will be presented at the American Heart Association's Scientific Sessions 2005 November 14, 2005 5:30 p.m. CT Dr. Ted W. Love, CEO & Chairman Dr. Michael Levy, SVP, Research & Development Dr. Steven Deitcher, VP, Medical Affairs Webcast: www.nuvelo.com
Live audio webcasts of the presentations will also be available online via the Investor Relations portion of Nuvelo's website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's clinical pipeline includes alfimeprase, a direct acting thrombolytic in Phase 3 trials for the treatment of acute peripheral arterial occlusion (PAO) and catheter occlusion and rNAPc2, an anticoagulant currently in Phase 2 trials that inhibits the factor VIIa and tissue factor complex. Nuvelo recently identified NU206 as a preclinical development candidate from its proprietary research programs and expects to leverage expertise in secreted proteins and antibody discovery to expand its pipeline and create partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.CONTACT: Nicole Estrin, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472, or nestrin@nuvelo.com
Web site: http://www.nuvelo.com/